Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Quest Diagnostics Incorporated

Healthcare US DGX

200.9USD
-0.68(0.34%)

Last update at 2026-03-10T20:00:00Z

Day Range

198.87204.39
LowHigh

52 Week Range

118.90155.14
LowHigh

Fundamentals

  • Previous Close 201.58
  • Market Cap15374.36M
  • Volume675816
  • P/E Ratio20.38
  • Dividend Yield2.08%
  • EBITDA1705.00M
  • Revenue TTM9297.00M
  • Revenue Per Share TTM82.82
  • Gross Profit TTM 3467.00M
  • Diluted EPS TTM6.71

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 1235.00M 2599.00M 1884.00M 1076.00M 926.00M
Minority interest -69.00000M -85.00000M 68.00M 48.00M 52.00M
Net income 946.00M 1995.00M 1431.00M 858.00M 736.00M
Selling general administrative 1818.00M 1727.00M 1550.00M 1457.00M 1424.00M
Selling and marketing expenses - - - - -
Gross profit 3433.00M 4209.00M 3633.00M 2689.00M 2605.00M
Reconciled depreciation 437.00M 408.00M 361.00M 329.00M 309.00M
Ebit 1428.00M 2381.00M 1971.00M 1231.00M 1097.00M
Ebitda 1810.00M 3158.00M 2408.00M 1580.00M 1406.00M
Depreciation and amortization 382.00M 777.00M 437.00M 349.00M 309.00M
Non operating income net other -11.00000M 447.00M 151.00M 77.00M 36.00M
Operating income 1428.00M 2381.00M 1971.00M 1231.00M 1101.00M
Other operating expenses 8455.00M 8407.00M 7466.00M 6495.00M 6426.00M
Interest expense 138.00M 151.00M 163.00M 175.00M 167.00M
Tax provision 264.00M 597.00M 460.00M 247.00M 182.00M
Interest income 138.00M 151.00M 163.00M 5.00M 2.00M
Net interest income -138.00000M -151.00000M -163.00000M -175.00000M -167.00000M
Extraordinary items - - 0.00000M 20.00M 14.00M
Non recurring - - - - -
Other items - - - - -
Income tax expense 264.00M 597.00M 460.00M 247.00M 182.00M
Total revenue 9883.00M 10788.00M 9437.00M 7726.00M 7531.00M
Total operating expenses 2005.00M 1828.00M 1662.00M 1458.00M 1500.00M
Cost of revenue 6450.00M 6579.00M 5804.00M 5037.00M 4926.00M
Total other income expense net -193.00000M 218.00M -87.00000M -155.00000M -12.00000M
Discontinued operations - - - 20.00M 20.00M
Net income from continuing ops 1015.00M 2080.00M 1499.00M 886.00M 744.00M
Net income applicable to common shares 942.00M 1988.00M 1431.00M 858.00M 736.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 12837.00M 13611.00M 14026.00M 12843.00M 11003.00M
Intangible assets 1092.00M 1167.00M 1167.00M 1121.00M 1207.00M
Earning assets - - - - -
Other current assets 196.00M 223.00M 157.00M 112.00M 144.00M
Total liab 6830.00M 7049.00M 7135.00M 7080.00M 5659.00M
Total stockholder equity 5893.00M 6444.00M 6759.00M 5641.00M 5216.00M
Deferred long term liab - - - - -
Other current liab 1072.00M 1243.00M 1187.00M 778.00M 782.00M
Common stock 2.00M 2.00M 2.00M 2.00M 2.00M
Capital stock 2.00M 2.00M 2.00M 2.00M 2.00M
Retained earnings 8290.00M 7649.00M 9303.00M 8174.00M 7602.00M
Other liab 812.00M 792.00M 847.00M 683.00M 652.00M
Good will 7220.00M 7095.00M 6873.00M 6619.00M 6563.00M
Other assets 144.00M 163.00M 1301.00M 64.00M 56.00M
Cash 315.00M 872.00M 1158.00M 1192.00M 135.00M
Cash and equivalents 315.00M 872.00M 1158.00M 1192.00M 135.00M
Total current liabilities 1551.00M 1753.00M 1776.00M 1990.00M 1485.00M
Current deferred revenue - - - - 17.00M
Net debt 4307.00M 3785.00M 3497.00M 4136.00M 3758.00M
Short term debt 155.00M 153.00M 143.00M 949.00M 464.00M
Short long term debt 2.00M 2.00M 2.00M 892.00M 562.00M
Short long term debt total 4622.00M 4657.00M 4655.00M 5328.00M 3893.00M
Other stockholder equity -2378.00000M -1193.00000M -2525.00000M -2496.00000M -2329.00000M
Property plant equipment 2351.00M 2304.00M 1627.00M 1453.00M 1288.00M
Total current assets 1898.00M 2741.00M 3058.00M 2490.00M 1390.00M
Long term investments 132.00M 141.00M 521.00M 482.00M 436.00M
Net tangible assets -1853.00000M -1818.00000M -700.00000M -1610.00000M -2477.00000M
Short term investments - - 521.00M - -
Net receivables 1195.00M 1438.00M 1520.00M 1063.00M 1012.00M
Long term debt 3978.00M 4010.00M 4013.00M 3966.00M 3429.00M
Inventory 192.00M 208.00M 223.00M 123.00M 99.00M
Accounts payable 324.00M 357.00M 446.00M 263.00M 222.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 37.00M 39.00M 50.00M 46.00M 51.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -21.00000M -14.00000M -21.00000M -39.00000M -59.00000M
Additional paid in capital - - - - -
Common stock total equity 2.00M 2.00M 2.00M 2.00M 2.00M
Preferred stock total equity - - - - -
Retained earnings total equity 8290.00M 7649.00M 9303.00M 8174.00M 7602.00M
Treasury stock -4673.00000M -3453.00000M -5366.00000M -5218.00000M -4996.00000M
Accumulated amortization - - - - -
Non currrent assets other 144.00M 163.00M 176.00M 160.00M 119.00M
Deferred long term asset charges - - - - -
Non current assets total 10939.00M 10870.00M 10968.00M 10353.00M 9613.00M
Capital lease obligations 642.00M 645.00M 640.00M 558.00M -
Long term debt total 3978.00M 4010.00M 4013.00M 3966.00M 3429.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -543.00000M 752.00M -772.00000M -411.00000M -801.00000M
Change to liabilities -180.00000M 35.00M 474.00M 102.00M -15.00000M
Total cashflows from investing activities -543.00000M 21.00M -772.00000M -411.00000M -801.00000M
Net borrowings -2.00000M -2.00000M -805.00000M 832.00M 124.00M
Total cash from financing activities -1732.00000M -2540.00000M -1267.00000M 225.00M -401.00000M
Change to operating activities 53.00M -9.00000M 3.00M -4.00000M 31.00M
Net income 1015.00M 2080.00M 1499.00M 906.00M 788.00M
Change in cash -557.00000M -286.00000M -34.00000M 1057.00M -2.00000M
Begin period cash flow 872.00M 1158.00M 1192.00M 135.00M 137.00M
End period cash flow 315.00M 872.00M 1158.00M 1192.00M 135.00M
Total cash from operating activities 1718.00M 2233.00M 2005.00M 1243.00M 1200.00M
Issuance of capital stock - - - - -
Depreciation 437.00M 408.00M 361.00M 329.00M 309.00M
Other cashflows from investing activities -139.00000M 424.00M -354.00000M -11.00000M -418.00000M
Dividends paid -305.00000M -309.00000M -297.00000M -286.00000M 266.00M
Change to inventory - -20.00000M - 29.00M 4.00M
Change to account receivables 246.00M 81.00M -455.00000M -63.00000M -65.00000M
Sale purchase of stock -1408.00000M -2199.00000M -325.00000M -353.00000M -322.00000M
Other cashflows from financing activities -17.00000M -159.00000M -29.00000M -87.00000M -36.00000M
Change to netincome 147.00M -257.00000M 123.00M -27.00000M 152.00M
Capital expenditures 404.00M 403.00M 418.00M 400.00M 383.00M
Change receivables 246.00M 81.00M -455.00000M -63.00000M -65.00000M
Cash flows other operating 53.00M -323.00000M 3.00M -4.00000M 31.00M
Exchange rate changes - - - - -
Cash and cash equivalents changes -557.00000M -286.00000M -34.00000M 1057.00M -2.00000M
Change in working capital 119.00M 87.00M 22.00M 35.00M -49.00000M
Stock based compensation 77.00M 79.00M 97.00M 56.00M 61.00M
Other non cash items 69.00M -364.00000M -59.00000M -98.00000M 18.00M
Free cash flow 1314.00M 1830.00M 1587.00M 843.00M 817.00M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DGX
Quest Diagnostics Incorporated		 -0.68 0.34% 200.90 20.38 14.90 1.63 2.36 2.14 12.44
TMO
Thermo Fisher Scientific Inc		 -9.89 1.94% 500.08 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.58 1.80% 195.22 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -1.21 1.04% 115.43 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -11.6 1.90% 598.85 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Quest Diagnostics Incorporated

500 Plaza Drive, Secaucus, NJ, United States, 07094

Key Executives

Name Title Year Born
Mr. Stephen H. Rusckowski Exec. Chairman 1957
Mr. James E. Davis CEO, Pres & Director 1963
Ms. Catherine T. Doherty Sr. VP of Regional Bus.es 1963
Mr. Sam A. Samad Exec. VP & CFO 1970
Mr. Michael J. Deppe VP, Corp. Controller & Chief Accounting Officer 1967
Ms. Gabrielle Wolfson Sr. VP and Chief Information & Digital Officer NA
Mr. Shawn C. Bevec VP of Investor Relations NA
Mr. Michael E. Prevoznik Sr. VP & Gen. Counsel 1962
Ms. Kristin Lee Wallace Esq. Sr. VP of Compliance NA
Mr. Gary D. Samuels Sr. VP & Chief Communications Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.